6640--Specimen Validity and Drug of Abuse of Abuse Reagent Supplies for the Minneapolis VA Health Care System
VETERANS AFFAIRS, DEPARTMENT OF
Place of performance: Minneapolis, MN
Free. Verify your email, then we send one reminder only.
- Posted
- Aug 28, 2026
- Closes
- No deadline published by the funder
Similar opportunities open now
- AN41--523-26-4-1865-0151: 10X Xenium Analyzer Recertification and PM (VA-26-00073846)Same funderOpenVETERANS AFFAIRS, DEPARTMENT OFNo deadline listed
- 6640--Notice of Intent to AwardSame funderOpenVETERANS AFFAIRS, DEPARTMENT OFNo deadline listed
- 6550--Glucose Accu-Chek® Test StripsSame funderOpenVETERANS AFFAIRS, DEPARTMENT OFNo deadline listed
- Q301--T-SPOT.TB Assay TestingSame funderOpenVETERANS AFFAIRS, DEPARTMENT OFNo deadline listed
- Q301 - IV Room Environmental TestingSame funderOpenVETERANS AFFAIRS, DEPARTMENT OFNo deadline listed
At a glance
This is a government contract opportunity posted by VETERANS AFFAIRS, DEPARTMENT OF in the in-vitro diagnostic substance manufacturing category. Work is performed in Minneapolis, MN.
Classification and identifiers
- Industry (NAICS)
- In-Vitro Diagnostic Substance Manufacturing (325413)
- Product or service (PSC)
- Laboratory Equipment and Supplies (6640)
- Solicitation number
- 36C26326Q0650_1
- Contracting office
- NETWORK CONTRACT OFFICE 23 (36C263)
Who can apply
About this opportunity
The Department of Veterans Affairs, Network Contracting Office 23 intends to award a sole source contract under the authority of FAR 6.103-1/FAR Overhaul 12.102(a) Only one responsible source and no other supplies will satisfy agency requirements, to Siemens Healthcare Diagnostics, Inc. for FDA approved specimen validity and Fentanyl reagents. These reagents will be used to verify the validity of specimens, including nitrite and creatinine assays, as well as perform Fentanyl testing in our highly specialized Forensic Toxicology Laboratory. This notice of intent is not a request for quotations; interested parties may express their interest by providing a capabilities statement no later than September 11, 2026, at 16:00 CT. The capabilities statement must provide clear and unambiguous eviden...